ROCHESTER, N.Y., May 12 /PRNewswire/ -- Integrated Nano-Technologies (INT), developer of a highly sensitive, accurate, nano-scale bioelectronic DNA identification platform, has appointed General Dennis J. Reimer, former Chief of Staff of the U.S. Army, and Richard J. Whitley, MD, world-renowned virologist, to its advisory panel. Both will play a substantial role in launching INT's innovative device, BioDetect(TM), which is now in the advanced testing stage. The technology provides rapid biological agent identification for the biosecurity and clinical diagnostics markets. "We are very pleased to have these distinguished leaders joining us on our advisory board," said Dr. Michael Connolly, CEO of INT. "Their expertise in biosecurity and virology will be instrumental as we continue to advance our technology for biological agent identification and other applications." General Reimer currently serves as Director of the National Memorial Institute for the Prevention of Terrorism (MIPT), whose mission is to "prevent and deter terrorism or mitigate the results." MIPT's focus is on the emergency responder community across the nation and they have sponsored research projects on how better to detect and protect against chemical, biological, radiological, nuclear and high explosive threats. Prior to being named Director of MIPT, Reimer served 37 years in the U.S. Army and was appointed the 33rd Chief of Staff, U.S. Army in 1995. Among his many accomplishments during his military career, General Reimer served as Commanding General of the United States Army, Forces Command, Fort McPherson, Georgia and as Deputy Chief of Staff for Operations in Korea. General Reimer's awards for peacetime and combat service include the Defense Distinguished Service Medal, the Distinguished Service Medal, two Legions of Merit, the Distinguished Flying Cross, six awards of the Bronze Star Medal, the Purple Heart and the Combat Infantryman Badge. Richard J. Whitley, MD, a world-renowned virologist, is currently involved in a federally funded scientific effort to study the diagnosis and treatment of potential biowarfare agents. He is Professor of Pediatrics, Microbiology and Medicine; Chair in Pediatrics; and Director, Division of Pediatric Infectious Diseases at the University of Alabama at Birmingham. Dr. Whitley has focused on developing and evaluating antiviral therapies for the treatment of encephalitis infections, and on the development of gene therapy approaches to antiviral and antitumor therapy. Dr. Whitley was honored with the Aventis Award by the American Society for Microbiology in 2000 and the International Society for Antiviral Research Award for distinguished scientific accomplishments in 1998. Dr. Whitley is presently an Editor of Antiviral Research, and is a member of the Editorial Boards of the Journal of Infectious Diseases, Sexually Transmitted Diseases, Reviews in MedicalVirology, Antimicrobial Agents and Chemotherapy, Antiviral Chemistry and Chemotherapy, Infectious Diseases Watch for Pediatricians, Seminars in Pediatric Infectious Diseases, Gene Therapy and Medscape Infectious Disease. About Integrated Nano-Technologies, LLC Rochester, NY-based Integrated Nano-Technologies, LLC is a leading innovator in highly accurate, sensitive, rapid, portable, electronic, biological agent identification technology. Built around the BioDetect(TM) Platform, INT's devices are highly portable and use disposable test cards to test field samples for numerous biological agents, including anthrax, in as little as 20 minutes. Future developments of the platform will enable the medical community to identify specific illness causing pathogens in patients without sending samples out to laboratories; facilitating faster and more accurate treatment regimens. For more information about Integrated Nano-Technologies, call 585-334-0170 or visit their Web site at www.integratednano.com. This press release contains forward-looking statements that are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
SOURCE Integrated Nano-Technologies